Otolaryngol Head Neck Surg:美国老年人群体中的咽鼓管功能障碍患病率

2020-07-15 AlexYang MedSci原创

最近,有研究人员调查了咽鼓管功能障碍(ETD)在美国老年人口中的患病率以及与其他上呼吸消化道炎症的相关性。

最近,有研究人员调查了咽鼓管功能障碍(ETD)在美国老年人口中的患病率以及与其他上呼吸消化道炎症的相关性。

研究是一个基于群体的代表性研究,共包括了147805名没有上呼吸消化道恶性肿瘤的患者和13804名匹配的患有上呼吸消化道恶性肿瘤的患者。患者年龄在66岁到99岁,时间为2003年到2011年。研究发现,ETD在无恶性肿瘤的患者中发病率为5.44%,在具有肿瘤的患者中为9.08%(OR, 1.73; 95%CI, 1.63-1.84)。对照群体中患有ETD的患者更可能诊断为慢性鼻炎(OR, 5.00;95%CI 4.70-5.33),慢性鼻窦炎(OR, 4.20;95%CI 3.98-4.43),过敏性鼻炎(OR, 4.27;95%CI 4.08-4.47)以及胃食管返流疾病(GERD)(OR, 2.42;95%CI 2.31-2.53)。患有ETD和慢性鼻炎(OR, 1.43;95%CI 1.24-1.65)、慢性鼻窦炎(1.57, 1.38-1.78)和急性中耳炎(1.33, 1.08-1.65)的患者与UADT恶性肿瘤更高的风险相关。

最后,研究人员指出,大于65岁患者诊断为ETD且无恶性肿瘤的比例不少于5%。另外,在没有UADT恶性肿瘤的情况下,ETD与慢性鼻炎、慢性鼻窦炎、过敏性鼻炎和胃食管反流病之间的相关性表明,一些ETD患者可能受益于炎症性疾病的治疗。

原始出处:

Jakob L Fischer , Charles A Riley , Mei-Chin Hsieh et al. Prevalence of Eustachian Tube Dysfunction in the US Elderly Population. Otolaryngol Head Neck Surg. 23 June 2020.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044147, encodeId=88bd204414eab, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 25 11:37:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717039, encodeId=adcb1e17039aa, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Sep 08 11:37:55 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250700, encodeId=56bd1250e0094, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421319, encodeId=38be142131958, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526765, encodeId=87f01526e6513, content=<a href='/topic/show?id=f37e8012213' target=_blank style='color:#2F92EE;'>#老年人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80122, encryptionId=f37e8012213, topicName=老年人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044147, encodeId=88bd204414eab, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 25 11:37:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717039, encodeId=adcb1e17039aa, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Sep 08 11:37:55 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250700, encodeId=56bd1250e0094, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421319, encodeId=38be142131958, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526765, encodeId=87f01526e6513, content=<a href='/topic/show?id=f37e8012213' target=_blank style='color:#2F92EE;'>#老年人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80122, encryptionId=f37e8012213, topicName=老年人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
    2020-09-08 xjy13
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044147, encodeId=88bd204414eab, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 25 11:37:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717039, encodeId=adcb1e17039aa, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Sep 08 11:37:55 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250700, encodeId=56bd1250e0094, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421319, encodeId=38be142131958, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526765, encodeId=87f01526e6513, content=<a href='/topic/show?id=f37e8012213' target=_blank style='color:#2F92EE;'>#老年人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80122, encryptionId=f37e8012213, topicName=老年人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2044147, encodeId=88bd204414eab, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 25 11:37:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717039, encodeId=adcb1e17039aa, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Sep 08 11:37:55 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250700, encodeId=56bd1250e0094, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421319, encodeId=38be142131958, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526765, encodeId=87f01526e6513, content=<a href='/topic/show?id=f37e8012213' target=_blank style='color:#2F92EE;'>#老年人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80122, encryptionId=f37e8012213, topicName=老年人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2044147, encodeId=88bd204414eab, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Dec 25 11:37:55 CST 2020, time=2020-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717039, encodeId=adcb1e17039aa, content=<a href='/topic/show?id=f8a98002eb1' target=_blank style='color:#2F92EE;'>#群体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80027, encryptionId=f8a98002eb1, topicName=群体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c0832353243, createdName=xjy13, createdTime=Tue Sep 08 11:37:55 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250700, encodeId=56bd1250e0094, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421319, encodeId=38be142131958, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526765, encodeId=87f01526e6513, content=<a href='/topic/show?id=f37e8012213' target=_blank style='color:#2F92EE;'>#老年人群#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80122, encryptionId=f37e8012213, topicName=老年人群)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jul 17 04:37:55 CST 2020, time=2020-07-17, status=1, ipAttribution=)]

相关资讯

WHO:将与美方讨论如何在确认有效后让更多人获得瑞德西韦

瑞德西韦获得美国FDA的紧急使用授权后,世卫组织开始关注这款治疗新冠潜在有效药物的可及性。

特朗普称相信年底将能研发出疫苗 专家:不现实

据美国《国会山报》报道,美国总统特朗普此前表示,将通过“曲速行动”快速将疫苗推向市场,相信年底将能够研发出疫苗,目标是到2021年1月份提供3亿份疫苗。然而,这一说法遭遇专家质

实地探访美国**儿童医院,揭秘新冠儿童患者的罕见症状

作为首批获准进入儿童重症监护病房的记者,美国国家公共电台(NPR)的露露·加西亚-纳瓦罗(Lulu Gracia-Navarro)于近日探访了位于华盛顿特区的美国国家儿童医院(Child

还没熬过疫情,美国这些医院就同时被护士和患者起诉了!

美国医疗公司Tenet Healthcare最近正在准备“迎接”患者的诉讼,这些患者声称在其旗下医院感染了新冠病毒。纽约一家护理工会也正起诉多家医院没有为前线医护人员提供足够的

美国研究发现新冠病毒新毒株成为主流,或易导致二次感染

环球网5月6日消息,据《洛杉矶时报》5日报道,由美国洛斯阿拉莫斯国家实验室的科学家领导的一项最新研究显示,科学家已经发现了一种新的新冠病毒毒株,而且似乎比新冠病毒大流行初期传播的毒株更具传染性。

警察暴行让美国医生都看不下去了:请立即停止!

乔治·弗洛伊德之死引发的抗议活动在全美持续蔓延之际,美国几家医生组织——美国儿科学会(AAP)、美国医学会(AMA)、美国医师协会(ACP)—&mda